T-Fovir A

Tenofovir Alafenamide


Each film coated tablet contains Tenofovir Alafenamide 25mg as Tenofovir Alafenamide Fumarate INN.


It is indicated for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease.

Dosage and Administration:

The recommended dosage is 25 mg (one tablet) taken orally once daily with food. Or, as directed by the registered physician.

No dosage adjustment of T-Fovir A is required in patients with mild, moderate, or severe renal impairment. It is not recommended in patients with end stage renal disease (estimated creatinine clearance below 15 ml/ min). No dosage adjustment is required in patients with mild hepatic impairment (Child-Pugh A). It is not recommended in patients with decompensated (Child-Pugh B or C) hepatic impairment.

Use in Pregnancy and Lactation:

There are no human data on the use of Tenofovir Alafenamide in pregnant women to inform a drug-associated risk of adverse fetal developmental outcome. It is not known whether Tenofovir Alafenamide and its metabolites are present in human breast milk, affect human milk production, or have effects on the breastfed infant.


Each box contains 10’s tablets in blister pack.

Prescribing Description

Related Products

© Copyright Drug International Ltd. 2024 Designed and Developed by ATI Limited.